A low starting dose of an oral GLP-1 is coming to market around $149 a month, against injectable versions that have run roughly $617 to $766 a month at net and can approach $1,200 at list. For the actuary building a self-funded employer plan's 2027 specialty pharmacy trend, that single price gap is the first reason in three years to consider that the GLP-1 line might bend downward rather than up. It is also a trap. Cheaper, easier-to-start oral therapy can expand the treated population fast enough that total spend rises even as the cost per prescription falls, and the same plans that are now carving back coverage could find demand returning through the front door of a pill. The 2027 pharmacy trend load and the stop-loss attachment point both depend on which of those forces wins, and the honest answer in June 2026 is that the line could move either way.
How GLP-1 Became the Specialty Trend's Biggest Single Driver
For three consecutive renewal cycles, GLP-1 agonists have been the line a pharmacy actuary pointed to first when explaining why the specialty trend assumption kept climbing. The drugs work, the eligible population for obesity and diabetes indications is enormous, and the per-member cost at injectable list prices put even modest utilization into the territory that moves a plan's total drug spend by points, not basis points. High-dollar GLP-1 claims grew 24% in the past year alone, and that growth landed on top of an already elevated base. A self-funded employer that added weight-loss coverage in 2023 or 2024 typically watched its GLP-1 line become one of the two or three largest single contributors to total pharmacy cost, which is exactly why the category became the first target when plan sponsors went looking for trend relief.
That history matters for 2027 because it sets the comparison base. A trend assumption is a statement about next year relative to this year, and the GLP-1 base is now large, fully ramped on injectables, and concentrated in plans that have already made a coverage decision one way or the other. Against that base, a meaningfully cheaper oral option does not enter a vacuum. It enters a book where the high-cost injectable utilization is already on the run rate, which is what makes the direction of the 2027 move genuinely ambiguous rather than obviously upward.
The Oral Launch and Two Ways the Curve Can Bend
An oral GLP-1 at a fraction of the injectable cost can pull the trend line in two opposite directions, and a defensible 2027 assumption has to model both. The downward path is unit-cost substitution: members already on therapy, or newly starting, move to a pill that costs the plan far less per month, the average cost per treated member falls, and if the treated population holds roughly flat the GLP-1 line bends down for the first time. The upward path is induced utilization. Oral administration removes the needle, the cold-chain handling, and a meaningful share of the hesitation that has kept many eligible members from starting, so a lower price can convert latent demand into prescriptions faster than substitution lowers the unit cost. A plan can easily end up paying less per member and covering far more members, with total spend higher than the injectable-only world it left.
Which force dominates is not a single number an actuary can look up; it is a function of plan design choices that are still being made. A plan that pairs the cheaper oral with tight utilization management, step therapy, and BMI or A1c eligibility gates is leaning toward the substitution outcome. A plan that opens the oral to broad obesity coverage without those controls is closer to the induced-demand outcome. The pricing actuary's job for 2027 is to set the trend load conditional on the plan's actual design, not on the headline drug price, and to widen the assumed range to reflect that the same molecule can produce opposite trend signals depending on how access is managed.
The unit-cost side is murkier than the headline prices suggest, which widens the range further. The $617 to $766 injectable figures are net of manufacturer rebates that pharmacy benefit managers negotiate and pass back to the plan unevenly, while the roughly $1,200 list price is closer to what an unrebated claim costs. An oral launch resets that rebate math, because a new product carries its own rebate trajectory and early in a launch the net discount is often thinner than on an established injectable facing competition. An actuary who models the oral purely at its low advertised price can overstate the substitution savings if the plan's actual net cost, after the PBM's rebate retention and the manufacturer's launch-period discounting, lands well above the sticker. The 2027 unit-cost assumption for the GLP-1 line has to be built on the plan's net economics, not the list-to-list comparison that makes the down-bend look automatic.
Employer Carve-Outs and the Coverage Question
The other reason the 2027 line is hard to call is that the coverage map is moving underneath it. Several large plans pulled back weight-loss GLP-1 coverage heading into 2026. Blue Cross Blue Shield of Massachusetts dropped obesity GLP-1 coverage for fully insured groups under 100 employees at the start of 2026, and Harvard Pilgrim and Blue Cross Blue Shield of Michigan moved to drop weight-loss GLP-1 coverage in 2026 as well. Those decisions were responses to the injectable cost curve, and a cheaper oral changes the arithmetic that produced them. An employer that carved out weight-loss coverage because a $700 monthly injectable was unaffordable may revisit that decision when the same clinical benefit is available at a fraction of the cost, which means a portion of the population that fell off the trend base in 2026 could re-enter it in 2027.
For the actuary, this turns the coverage assumption into a pricing variable rather than a fixed input. The 2027 trend for a given employer depends not only on the drug price and the utilization response but on whether the plan reverses, maintains, or extends a coverage carve-out, and on whether the population that left will return at the lower price point. Pricing a renewal without an explicit, documented coverage assumption for the GLP-1 line risks setting a trend that is internally inconsistent with the plan design the employer actually adopts.
Setting a 2027 Pharmacy Trend Load Around a Two-Sided Risk
Most pharmacy trend assumptions are built as a single point estimate, a blended percentage applied to the prior year's allowed cost, decomposed into unit cost, utilization, and mix. The GLP-1 line breaks that habit because its 2027 unit-cost and utilization components are negatively correlated in a way that the rest of the book is not: the same event, a cheap oral launch, pushes unit cost down and utilization up at once. Setting a single blended trend for the category buries that dynamic. The more defensible approach is to model the GLP-1 line separately, with explicit scenarios for substitution-dominant and utilization-dominant outcomes, and to carry the category's contribution to total trend as a range rather than a point. Employers buying renewals on a single trend number should at least see the GLP-1 sensitivity behind it, because the category is large enough that a wrong sign on its move can swamp the accuracy of the rest of the build.
This is also where credibility and data lag bite. The oral launch is recent, so the plan's own experience will not yet show how its members respond, and national utilization data will lag further. An actuary setting the 2027 load is therefore relying on early launch data, pharmacy benefit manager projections, and judgment about the specific plan's access controls, none of which is fully credible. That argues for setting the assumption with an explicit margin and revisiting it mid-year as real substitution and utilization data emerge, rather than locking a point estimate into a renewal that will not be retrofitted until the following cycle.
The Stop-Loss Layer Stays Hot Regardless
Even if the GLP-1 line bends down, the stop-loss attachment that sits above a self-funded plan does not get quiet, because the forces driving large claims are largely independent of the GLP-1 question. Million-dollar claims rose 46% from 2022 to 2026, and the drivers are catastrophic rather than chronic: cell and gene therapies such as Elevidys at roughly $3.6 million per patient, complex oncology, and premature-birth and transplant cases that can each pierce a specific stop-loss layer on their own. Overall employer health-cost trend is still running near 10% for 2026, so the medical side of the renewal is not offering relief that would let a plan sponsor relax about the catastrophic layer.
The practical implication is that a softer GLP-1 trend, if it materializes, lowers the expected pharmacy spend in the working layer but does little for the specific and aggregate stop-loss pricing, which is driven by the tail. An actuary pricing the full self-funded program in 2027 should resist letting an optimistic GLP-1 assumption flow through to the stop-loss attachment, because the gene-therapy and high-cost-claimant frequency that sets the attachment point is on its own trajectory. The two layers can move in opposite directions in the same renewal, and conflating them understates the catastrophic exposure.
What the 2027 Renewal Has to Account For
The oral GLP-1 launch is the first event in years that gives a pharmacy actuary a credible reason to write a flat or declining GLP-1 trend into a 2027 self-funded renewal, and also the first that could quietly double the treated population at a lower unit cost. The responsible move is to price the line as a two-sided risk: model substitution and induced utilization separately, tie the trend explicitly to the plan's coverage decision and access controls, carry the category as a range rather than a point, and keep the stop-loss attachment anchored to the catastrophic-claim trajectory rather than to the GLP-1 story. Plans and brokers that treat the cheaper oral as an unambiguous trend win will be surprised in either direction, and the actuary who showed the sensitivity will be the one who priced the renewal honestly.
Further Reading
- The 2026 Milliman Medical Index pharmacy decomposition – how a 14.8% pharmacy trend breaks down into the components a renewal has to model.
- Employer health costs at a 15-year high – the medical-side trend that keeps the full self-funded renewal under pressure.
- The GLP-1 credibility gap in 2027 ACA filings – the same drug class viewed through the individual-market lens, where the credibility problem looks different.
- CMS GLP-1 bridge and the $50 Part D copay – how the GLP-1 cost question is being handled inside Medicare Part D pricing.
- Oral Wegovy enters workers compensation – the same launch reshaping severity in a different line.